Medicare Advantage Enrollment and Access to Kidney Transplant After the 21st Century Cures Act

In the first 3 years following the 21st Century Cures Act, Medicare Advantage beneficiaries with ESKD had substantially lower transplant and wait-listing rates than traditional Medicare beneficiaries. Policy oversight may be needed to monitor access for this critical, high-value treatment for kidney failure among the rapidly growing Medicare Advantage population.

Corresponding Author: Amal N. Trivedi, MD, MPH, Department of Health Services, Policy, and Practice, Brown University School of Public Health, 121 S Main St, Floor 6, Providence, RI 02903 (amal_trivedi@brown.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.